[HTML][HTML] Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and …

A Babajani, K Moeinabadi-Bidgoli, F Niknejad… - Stem Cell Research & …, 2022 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus
disease 2019 (COVID-19), has become in the spotlight regarding the serious early and late …

[HTML][HTML] Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?

RN Riedel, A Pérez-Pérez, V Sánchez-Margalet… - Stem Cell Research & …, 2021 - Springer
A new coronavirus respiratory disease (COVID-19) caused by the SARS-CoV-2 virus,
surprised the entire world, producing social, economic, and health problems. The COVID-19 …

[HTML][HTML] Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia—a regenerative dogma

SE Siddesh, DM Gowda, R Jain, A Gulati… - Stem cell …, 2021 - ncbi.nlm.nih.gov
With a robust rise in the number of COVID-19 cases, the World Health Organization (WHO)
has declared COVID-19 as a pandemic on 11 th March 2020. COVID-19 pandemic has …

[HTML][HTML] Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

SMR Hashemian, R Aliannejad, M Zarrabi… - Stem cell research & …, 2021 - Springer
Background Acute respiratory distress syndrome (ARDS) is a fatal complication of
coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human …

[HTML][HTML] Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms

NK Farkhad, A Mahmoudi, E Mahdipour - Regenerative Therapy, 2022 - Elsevier
COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2), started in December 2019 in Wuhan, China, and quickly became the global …

[HTML][HTML] Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I …

HR Aghayan, F Salimian, A Abedini… - Stem cell research & …, 2022 - Springer
Background High morbidity and mortality rates of the COVID-19 pandemic have made it a
global health priority. Acute respiratory distress syndrome (ARDS) is one of the most …

[HTML][HTML] Facing the challenges in the COVID-19 pandemic era: from standard treatments to the umbilical cord-derived mesenchymal stromal cells as a new therapeutic …

E Russo, S Corrao, F Di Gaudio, G Alberti, M Caprnda… - Cells, 2023 - mdpi.com
Coronavirus disease 2019 (COVID-19), the pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), which counts more than 650 million cases and …

Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study

M Dauletova, H Hafsan, N Mahhengam, AO Zekiy… - Clinical …, 2021 - Elsevier
In the past year, an emerging disease called Coronavirus disease 2019 (COVID-19), caused
by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been discovered in …

[HTML][HTML] Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective

A Gupta, S Kashte, M Gupta, HC Rodriguez… - Human cell, 2020 - Springer
Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-
related morbidity and mortality. Recent clinical evidences suggest increased level of …

[HTML][HTML] Mesenchymal stem cells (MSCs) as a potential therapeutic strategy in COVID-19 patients: literature research

A Coelho, RD Alvites, MV Branquinho… - Frontiers in cell and …, 2020 - frontiersin.org
In 2019, an outbreak of an unknown coronavirus–SARS-CoV-2–responsible for COVID-19
disease, was first reported in China, and evolved into a pandemic of huge dimensions and …